BCL2L11 and small cell lung carcinoma: Based on our results in this study, we propose the following model as the mechanism of ganetespib and venetoclax treatment in BCL-2-high SCLC cells (Figure 8): (A) The inhibition of HSP90 triggers Onc-p53 degradation, followed by BIM induction.